Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5910714 | 0.85 | KEAP1 (0.58) | KDM4ESMN1; SMN2KEAP1ALDH1A1CYP1A2 | |
| SCHEMBL4398797 | 0.83 | KEAP1 (0.56) | KDM4ESMN1; SMN2KEAP1ALDH1A1CYP1A2 | |
| SCHEMBL235080 | 0.83 | KDM4E (0.65) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA | |
| SCHEMBL6044315 | 0.80 | GLA (0.47) | KDM4ESMN1; SMN2KEAP1ALDH1A1CYP1A2 | |
| SCHEMBL674062 | 0.80 | ALDH1A1 (0.52) | KDM4ESMN1; SMN2KEAP1ALDH1A1CYP1A2 | |
| SCHEMBL20329460 | 0.80 | SMN1; SMN2 (0.46) | KDM4ESMN1; SMN2KEAP1ALDH1A1CYP1A2 | |
| SCHEMBL6077409 | 0.80 | KDM4E (0.46) | KDM4ESMN1; SMN2KEAP1ALDH1A1CYP1A2 | |
| SCHEMBL10501656 | 0.80 | KEAP1 (0.52) | KDM4ESMN1; SMN2KEAP1ALDH1A1CYP1A2 | |
| SCHEMBL18434868 | 0.80 | KDM4E (0.46) | KDM4ESMN1; SMN2KEAP1ALDH1A1CYP1A2 | |
| SCHEMBL10913328 | 0.80 | KDM4E (0.70) | KDM4ESMN1; SMN2KEAP1ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1100816-B1 | AEROTHRICIN ANALOGS, THEIR PREPARATION AND USE | BASILEA PHARMACEUTICA AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| EP-1251827-B1 | NASALLY ADMINISTRABLE ANTIFUNGAL CYCLIC PEPTIDE COMPOSITIONS | BASILEA PHARMACEUTICA AG (CH) | 2004-05-26 | — | — | EP | disclosed |
| US-6489440-B1 | Cyclic compounds | BASILEA PHARMACEUTICA AG (CH) | 2002-12-03 | — | — | US | disclosed |
| EP-1251827-A2 | NASALLY ADMINISTRABLE CYCLIC PEPTIDE COMPOSITIONS | Basilea Pharmaceutica AG (CH) | 2002-10-30 | — | — | EP | disclosed |
| US-20010038824-A1 | Intranasal cyclic peptide formulations | BASILEA PHARMACEUTICA AG (CH) | 2001-11-08 | — | — | US | disclosed |
| WO-2001052894-A2 | NASALLY ADMINISTRABLE CYCLIC PEPTIDE COMPOSITIONS | BASILEA PHARMACEUTICA AG (CH) | 2001-07-26 | — | — | WO | disclosed |
| EP-1090031-A1 | SUBSTITUTED CYCLOOCTADEPSIPEPTIDES | Bayer Aktiengesellschaft (DE) | 2001-04-11 | — | — | EP | disclosed |
| WO-1999067281-A1 | SUBSTITUTED CYCLOOCTADEPSIPEPTIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010038824-A1 | Intranasal cyclic peptide formulations | VIP, NPPA, SSTR5 | KDM4E 4833/4885SMN1; SMN2 4377/4885KEAP1 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.